Lyka Labs
: LYKALABS · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Lyka Labs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Lyka Labs Ltd is a pharmaceutical company engaged in the development, manufacture, and marketing of finished dosages and active pharmaceutical ingredients. The company specialises in therapeutic segments including lyophilised injections and various topical formulations such as creams, ointments, and gels.
Business Model
The company generates revenue through the manufacturing and sale of WHO-GMP and ISO 9001-certified pharmaceutical formulations. It operates across both domestic and international markets by leveraging its technical expertise in lyophilisation and topical drug delivery systems.
- Certifications:WHO-GMP, ISO 9001
Growth Outlook
Growth is expected to be driven by the company's focus on expanding its portfolio of specialised injectable and topical products. Continued adherence to international quality standards supports potential market penetration in regulated pharmaceutical markets.
Key Risks
- Regulatory Compliance. Failure to maintain WHO-GMP and other international quality standards could lead to product recalls or export bans.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials may adversely impact profit margins.
- Competitive Pressure. The pharmaceutical sector is highly fragmented, leading to intense price competition and margin erosion for generic formulations.
- Currency Risk. As an exporter, the company is exposed to foreign exchange rate fluctuations which can affect the profitability of international operations.
Start your research today
Unlock AI insights, financials, peers and live data on Lyka Labs and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Lyka LabsLYKALABS | ₹267 Cr | — | — | — | -3.0% | — | — | -24.8% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Lyka Labs
: LYKALABS · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Lyka Labs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Lyka Labs Ltd is a pharmaceutical company engaged in the development, manufacture, and marketing of finished dosages and active pharmaceutical ingredients. The company specialises in therapeutic segments including lyophilised injections and various topical formulations such as creams, ointments, and gels.
Business Model
The company generates revenue through the manufacturing and sale of WHO-GMP and ISO 9001-certified pharmaceutical formulations. It operates across both domestic and international markets by leveraging its technical expertise in lyophilisation and topical drug delivery systems.
- Certifications:WHO-GMP, ISO 9001
Growth Outlook
Growth is expected to be driven by the company's focus on expanding its portfolio of specialised injectable and topical products. Continued adherence to international quality standards supports potential market penetration in regulated pharmaceutical markets.
Key Risks
- Regulatory Compliance. Failure to maintain WHO-GMP and other international quality standards could lead to product recalls or export bans.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials may adversely impact profit margins.
- Competitive Pressure. The pharmaceutical sector is highly fragmented, leading to intense price competition and margin erosion for generic formulations.
- Currency Risk. As an exporter, the company is exposed to foreign exchange rate fluctuations which can affect the profitability of international operations.
Start your research today
Unlock AI insights, financials, peers and live data on Lyka Labs and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026